Actively Recruiting
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
Led by Washington University School of Medicine · Updated on 2026-04-23
15
Participants Needed
1
Research Sites
297 weeks
Total Duration
On this page
Sponsors
W
Washington University School of Medicine
Lead Sponsor
G
Genentech, Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
This phase 1 pilot study examines the feasibility and safety of mosunetuzumab after autologous stem cell transplant for patients with aggressive B cell lymphomas. Mosunetuzumab is an antibody that has been engineered to attach to two target cells in the immune system: T cells that normally perform tasks like killing virus-infected cells, and cancerous B cells. Mosunetuzumab has been designed to direct these T cells to kill the cancerous B cells instead.
CONDITIONS
Official Title
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of relapsed or refractory CD20-positive large B cell lymphoma, high-grade B cell lymphoma, transformed B cell lymphoma, primary mediastinal B cell lymphoma, or follicular lymphoma grade 3B
- Planning to undergo autologous stem cell transplantation after two or more prior lines of lymphoma therapy
- At least 18 years of age
- Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less
- Women of childbearing potential and men must agree to use effective contraception prior to enrollment, during treatment, and for 3 months after the last dose of mosunetuzumab
- Ability to understand and sign informed consent
- Adequate hematologic function and normal laboratory values at post-transplant screening
- Status post autologous stem cell transplantation after two or more prior lines of therapy for lymphoma
You will not qualify if you...
- Chemotherapy-resistant lymphoma at pre-transplant assessment
- History of severe immune-related adverse events from prior immunotherapy
- History of macrophage activation syndrome or hemophagocytic lymphohistiocytosis unrelated to lymphoma, or unresolved lymphoma-related HLH
- Recent or current significant central nervous system disease or pathology
- Prior allogeneic stem cell transplant or solid organ transplant
- History of severe allergic reactions to monoclonal antibodies or hypersensitivity to mosunetuzumab components
- History of severe rash or blistering after immunomodulatory treatment
- Chronic active Epstein-Barr virus infection
- Significant liver disease or active hepatitis B or C infection
- Known HIV infection
- History of progressive multifocal leukoencephalopathy
- Other malignancies that may interfere with study compliance or results, except certain treated cancers in remission
- Active autoimmune disease requiring treatment or certain autoimmune conditions without proper control
- Significant uncontrolled cardiovascular or pulmonary disease
- Pregnancy, lactation, or intention to become pregnant during the study
- Use of systemic immunosuppressive medications within 2 weeks prior to treatment start
- Active infections requiring IV antibiotics within 1 week prior to treatment
- Recent major surgery within 28 days prior to treatment
- Use of live vaccines within 4 weeks before treatment or during study until B-cell recovery
- Clinically significant unresolved toxicities from prior treatment
- Clinical evidence of lymphoma progression after transplant
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Washington University School of Medicine
St Louis, Missouri, United States, 63110
Actively Recruiting
Research Team
A
Armin Ghobadi, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here